Sluggish performance in India and US market led to fall in revenue and increase in cost dipped the profit | Glenmark Pharmaceuticals Q1 FY23 Result & Earning Call Highlights
Sluggish performance in India and US market led to fall in revenue and increase in cost dipped the profit | Glenmark Pharmaceuticals Q1 FY23 Result & Earning Call Highlights
Sluggish performance in India and US market led to fall in revenue and increase in cost dipped the profit | Glenmark Pharmaceuticals Q1 FY23 Result & Earning Call Highlights